Vidyya Medical News Service
*
Volume 5 Issue 47 Published - 14:00 UTC 08:00 EST 16-Feb-2003 Next Update - 14:00 UTC 08:00 EST 17-Feb-2003
little clear gif used for spacer
.
*

CONTEXT trial compares GW433908/Ritonavir to Lopinavir/Ritonavir
Preliminary 24-week data were presented this week from the CONTEXT trial, an open-label, multi-center study evaluating the safety and efficacy of once-a-day (QD) or twice-a-day (BID) dosing of the investigational protease inhibitor (PI) GW433908 (908) boosted with ritonavir (908/r) compared to a third treatment arm with the PI lopinavir/ritonavir (LPV/r, Kaletra®) BID in treatment-experienced patients with prior virologic failure.  more

*
NEAT study results compare GW433908 (908) to Nelfinavir
Final 48-week results from the NEAT trial, an open-label, multi-center study evaluating the safety and efficacy of the investigational protease inhibitor (PI) GW433908 (908) in antiretroviral therapy-naive HIV+ patients versus nelfinavir (NFV/Viracept ®), were presented at the 10th Conference on Retroviruses and Opportunistic Infections. more

 


*
Results of the 2NN study show no statistical difference between Viramune ®(Nevirapine) and Sustiva ® (Efavirenz)
Results of the 2NN study show no statistical difference between Viramune(nevirapine, Boehringer Ingelheim) and Sustiva ® (Efavirenz), Bristol Myers Squibb Company) in anti-HIV efficacy with respect to viral suppression and immune restoration at 48 weeks. 2NN is the first large-scale, prospective randomized trial directly comparing non-nucleoside reverse transcriptase inhibitor- (NNRTI) containing regimens in patients initiating anti-HIV therapy.  more

*
Changes in prevalence of mutations associated with HIV treatment failure: Resistance data on mutation patterns can help predict future treatment options
The results from a longitudinal study of the relative frequency of various types of HIV mutations associated with the use of antiretroviral therapy (ART) were presented this week at a meeting of leading AIDS researchers. The study showed that the prevalence of most key mutations associated with antiretroviral resistance have changed significantly from 1999-2002. more

*
Resistance data presented show early use of atazanavir may lead to increased viral susceptibility to other protease inhibitors
Bristol-Myers Squibb Company presented resistance data this week at a medical meeting in Boston from several Phase II and Phase III studies of atazanavir, an investigational protease inhibitor (PI) under development for the treatment of HIV/AIDS. The data suggest that the I50L is the signature amino acid change following atazanavir treatment that results in atazanavir-specific resistance and increased susceptibility to all other PIs.  more

 
little clear gif used for a space